AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2195734 — intervention group
Group type: EXPERIMENTAL
Intervention: cyclosporin (Cs) treatment
Number of subjects: 188
Study 2195734 — intervention group
Group type: COMPARATOR
Intervention: placebo treatment
Number of subjects: 188
Study 154624 — intervention group
Group type: EXPERIMENTAL
Intervention: Arecoline (cholinergic agonist)
Number of subjects: 6
Study 31195828 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-day Acceptance and Commitment Therapy workshop
Number of subjects: 67
Study 31195828 — intervention group
Group type: EXPERIMENTAL
Intervention: PROMIS Anxiety Short Form 8a
Number of subjects: 67
Study 31195828 — intervention group
Group type: EXPERIMENTAL
Intervention: PROMIS Depression Short Form 8b
Number of subjects: 67
Study 31195828 — intervention group
Group type: EXPERIMENTAL
Intervention: PROMIS Pain Interference Short Form 8a
Number of subjects: 67
Study 31195828 — intervention group
Group type: EXPERIMENTAL
Intervention: PROMIS Anxiety Short Form 8a and PROMIS Depression Short Form 8b
Number of subjects: 67
Study 30679036 — intervention group
Group type: EXPERIMENTAL
Intervention: RYGB
Number of subjects: 100
Study 30679036 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 100
Study 28158981 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved clinical service delivery through the BHOMA trial in 46 clinics
Number of subjects: 318380
Study 28158981 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive medication availability
Number of subjects: 318380
Study 28158981 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring hypertension process indicators
Number of subjects: 318380
Study 28158981 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient visit attendance
Number of subjects: 318380
Study 28158981 — intervention group
Group type: EXPERIMENTAL
Intervention: Chart recorded hypertension diagnosis
Number of subjects: 318380
Study 26232911 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 g of low-fat lamb per day
Number of subjects: 20
Study 26232911 — intervention group
Group type: COMPARATOR
Intervention: 250 g of high-fat lamb per day
Number of subjects: 20
Study 23957603 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation (Ecologic 825, Winclove, Amsterdam, the Netherlands) for 8 weeks after 4 weeks of antibiotics
Number of subjects: 16
Study 23957603 — intervention group
Group type: COMPARATOR
Intervention: Active pouchitis
Number of subjects: 16
Study 23957603 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment
Number of subjects: 16
Study 23957603 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation
Number of subjects: 16
Study 23957603 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics or probiotics
Number of subjects: 16
Study 23957603 — intervention group
Group type: COMPARATOR
Intervention: Healthy pouch (control)
Number of subjects: 16
Study 21427431 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil/Armodafinil
Number of subjects: 190
Study 21427431 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study 18955523 — intervention group
Group type: EXPERIMENTAL
Intervention: OPT-80
Number of subjects: 0
Study 18955523 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 0
Study 15863861 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% adapalene gel
Number of subjects: 105
Study 15863861 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% benzoyl peroxide lotion
Number of subjects: 105
Study 15863861 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 0.1% adapalene gel + 5% benzoyl peroxide
Number of subjects: 105
Study 12423709 — intervention group
Group type: EXPERIMENTAL
Intervention: ezetimibe 10 mg
Number of subjects: 892
Study 12423709 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 892
Study 10716064 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiludronate 400 mg
Number of subjects: 153
Study 10716064 — intervention group
Group type: COMPARATOR
Intervention: Pilot model development data set
Number of subjects: 153
Study 7793555 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine/glycopyrronium mixture
Number of subjects: 28
Study 7793555 — intervention group
Group type: COMPARATOR
Intervention: Saline 0.9%
Number of subjects: 28
Study 1954639 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginseng extract combined with dimethylaminoethanol bitartrate, vitamins, minerals, and trace elements
Number of subjects: 50
Study 1954639 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 1954639 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginseng extract
Number of subjects: 50
Study 7447218 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of methylprednisolone, intravenously, once a month for 6 months
Number of subjects: 10
Study 7447218 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30554073 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab plus FOLFIRI
Number of subjects: 491
Study 30554073 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab plus FOLFIRI
Number of subjects: 491
Study 27465403 — intervention group
Group type: EXPERIMENTAL
Intervention: Web conferencing or telephones connecting caregivers with hospice care team during care plan meetings
Number of subjects: 446
Study 27465403 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 446
Study 25912520 — intervention group
Group type: EXPERIMENTAL
Intervention: Quest to Lava Mountain (QTLM) computer game, implemented for 90 min/week for 6 weeks
Number of subjects: 94
Study 25912520 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher QTLM exposure and gaming progress
Number of subjects: 94
Study 25912520 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (no QTLM exposure)
Number of subjects: 94
Study 24608310 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium picosulfate with a prepackaged low-residue diet
Number of subjects: 194
Study 24608310 — intervention group
Group type: COMPARATOR
Intervention: 4-L PEG solution
Number of subjects: 194
Study 22859343 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive spirometer exercise (ISE) plus conventional exercise (CE); n=23
Number of subjects: 46
Study 22859343 — intervention group
Group type: COMPARATOR
Intervention: Conventional exercise (CE) alone; n=23
Number of subjects: 46
Study 19958854 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalcetrapib 600 mg daily
Number of subjects: 15600
Study 19958854 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 15600
Study 17716288 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipo Cream
Number of subjects: 20
Study 17716288 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipo Milk
Number of subjects: 20
Study 17716288 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipo Ointment
Number of subjects: 20
Study 17716288 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 20
Study 15207957 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 5006
Study 15207957 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 5006
Study 15207957 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Valsartan and Amlodipine
Number of subjects: 5006
Study 11756949 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (FK506) 0.1% ointment
Number of subjects: 16
Study 11756949 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate 0.1% ointment
Number of subjects: 16
Study 11756949 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 16
Study 9520627 — intervention group
Group type: EXPERIMENTAL
Intervention: Active clinical rehabilitation involving systematic perturbation of sitting posture using submaximal reaching movements over four reaching distances.
Number of subjects: 2
Study 8083390 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflight exercise (experimental)
Number of subjects: 78
Study 8083390 — intervention group
Group type: COMPARATOR
Intervention: Restricted activity (control)
Number of subjects: 78
Study 2683189 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine
Number of subjects: 611
Study 2683189 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 611
Study 956798 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist self-reported behavioral arousal during therapy
Number of subjects: 18
Study 956798 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiological activation during therapy (measured by electromyogram, heart rate, blood pressure, skin conductance)
Number of subjects: 18
Study 956798 — intervention group
Group type: COMPARATOR
Intervention: Difficulty of the patient (easy vs difficult-to-interview)
Number of subjects: 18
Study 31008776 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid intervention plus standard care
Number of subjects: 30
Study 31008776 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 30
Study 31721936 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Training (ST)
Number of subjects: 58
Study 31721936 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Training combined with Electrical Muscle Stimulation (ST+EMS)
Number of subjects: 58
Study 31721936 — intervention group
Group type: COMPARATOR
Intervention: Untrained Control (UN)
Number of subjects: 58
Study 27868384 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-acute group exercise program
Number of subjects: 422
Study 27868384 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 422
Study 26608727 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct access to low-dose computed tomography (LDCT) from primary care combined with a 1 h lung cancer update meeting.
Number of subjects: 331
Study 26608727 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care without direct access to LDCT).
Number of subjects: 331
Study 22761006 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans-dermal nicotine patches and cognitive behavioral therapy (Group 1)
Number of subjects: 52
Study 22761006 — intervention group
Group type: COMPARATOR
Intervention: Cognitive behavioral therapy alone (Group 2)
Number of subjects: 52
Study 22165113 — intervention group
Group type: EXPERIMENTAL
Intervention: Ni‐Cr alloy PFM crown
Number of subjects: 30
Study 22165113 — intervention group
Group type: EXPERIMENTAL
Intervention: Co‐Cr alloy PFM crown
Number of subjects: 30
Study 22165113 — intervention group
Group type: COMPARATOR
Intervention: Au‐Pt alloy PFM crown
Number of subjects: 30
Study 18322027 — intervention group
Group type: EXPERIMENTAL
Intervention: DESMOND education sessions
Number of subjects: 36
Study 18322027 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 36
Study 16801465 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril (target, 4 mg/d)
Number of subjects: 8290
Study 16801465 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8290
Study 12732391 — intervention group
Group type: EXPERIMENTAL
Intervention: Unopposed 17beta-estradiol administered for a 2-year treatment period
Number of subjects: 199
Study 10819344 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefpodoxime-proxetil, 8 mg/kg/day in two divided doses for 5 days followed by 5 days of placebo
Number of subjects: 450
Study 10819344 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefpodoxime-proxetil, 8 mg/kg/day in two divided doses for 10 days
Number of subjects: 450
Study 9082341 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPD treatment
Number of subjects: 10
Study 9082341 — intervention group
Group type: COMPARATOR
Intervention: Control group (40 healthy young male volunteers)
Number of subjects: 10
Study 1797696 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg carteolol/day
Number of subjects: 12
Study 1797696 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6683554 — intervention group
Group type: COMPARATOR
Intervention: Bifonazole cream 1%, solution 1%, gel 1%, and powder 1% administered once daily for 2 or 3 weeks
Number of subjects: 1129
Study 31419271 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 25mg per day for 12 months
Number of subjects: 33
Study 31419271 — intervention group
Group type: COMPARATOR
Intervention: Control group (no spironolactone)
Number of subjects: 33
Study 31419271 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone group
Number of subjects: 33
Study 31419271 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 33
Study 29228436 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomized inhalation of ipratropium bromide and budesonide suspension, oxygen flow 3-5 L/min, 15-20 min/time, twice a day for 1 week
Number of subjects: 86
Study 29228436 — intervention group
Group type: COMPARATOR
Intervention: Control group received routine treatment including saline through a ventilator mask
Number of subjects: 86
Study 29228436 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomized inhalation of ipratropium bromide and budesonide suspension
Number of subjects: 86
Study 26435087 — intervention group
Group type: EXPERIMENTAL
Intervention: InterX5000 treatment
Number of subjects: 25
Study 26435087 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 25
Study 26435087 — intervention group
Group type: COMPARATOR
Intervention: Baseline comparison with asymptomatic subjects
Number of subjects: 25
Study 24354496 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg/day for 4 weeks
Number of subjects: 16
Study 24354496 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline 50 mg/day for 4 weeks
Number of subjects: 16
Study 24354496 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group (no treatment)
Number of subjects: 16
Study 22933498 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid
Number of subjects: 159
Study 22933498 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid
Number of subjects: 159
Study 22933498 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study 19476406 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine-timolol (BID) as monotherapy
Number of subjects: 180
Study 19476406 — intervention group
Group type: COMPARATOR
Intervention: Dorzolamide-timolol (BID) as monotherapy
Number of subjects: 180
Study 19476406 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine-timolol (BID) as adjunctive therapy to PGA
Number of subjects: 180
Study 19476406 — intervention group
Group type: COMPARATOR
Intervention: Dorzolamide-timolol (BID) as adjunctive therapy to PGA
Number of subjects: 180
Study 19476406 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine-timolol
Number of subjects: 180
Study 19476406 — intervention group
Group type: COMPARATOR
Intervention: Dorzolamide-timolol
Number of subjects: 180
Study 17890171 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure lowering with perindopril/indapamide combination
Number of subjects: 0
Study 17890171 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glucose control using gliclazide MR based regimen
Number of subjects: 0
Study 15337535 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 months of flutamide and goserelin before RT
Number of subjects: 378
Study 15337535 — intervention group
Group type: COMPARATOR
Intervention: 3 months of flutamide and goserelin before RT
Number of subjects: 378
Study 11136837 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg/day)
Number of subjects: 13388
Study 11136837 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13388
Study 11742422 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-oriented reconditioning programme (3-4 weeks, 3-7 hours of walks in hilly ground three times a week)
Number of subjects: 173
Study 11742422 — intervention group
Group type: COMPARATOR
Intervention: Standard programme with a mix of passive and active elements
Number of subjects: 173
Study 9313005 — intervention group
Group type: COMPARATOR
Intervention: Antileukotrienes
Number of subjects: 0
Study 8120830 — intervention group
Group type: EXPERIMENTAL
Intervention: Running with normal arm movements
Number of subjects: 34
Study 8120830 — intervention group
Group type: EXPERIMENTAL
Intervention: Running without arm movements
Number of subjects: 34
Study 8120830 — intervention group
Group type: EXPERIMENTAL
Intervention: Running with breathing paced by an acoustic signal
Number of subjects: 34
Study 8120830 — intervention group
Group type: EXPERIMENTAL
Intervention: Running with high degree of co-ordination
Number of subjects: 34
Study 8120830 — intervention group
Group type: COMPARATOR
Intervention: Cycling
Number of subjects: 34
Study 3551645 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-suction drains (Group I)
Number of subjects: 128
Study 3551645 — intervention group
Group type: COMPARATOR
Intervention: Penrose drains (Group II)
Number of subjects: 128
Study 28158582 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVR
Number of subjects: 232
Study 28158582 — intervention group
Group type: COMPARATOR
Intervention: SAVR
Number of subjects: 232
Study 26855107 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel contraceptive implant (150 mg), initiated immediately
Number of subjects: 414
Study 26855107 — intervention group
Group type: COMPARATOR
Intervention: Control group (3-month delay in implant initiation)
Number of subjects: 414
Study 26855107 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel contraceptive implant (150 mg)
Number of subjects: 414
Study 24813167 — intervention group
Group type: EXPERIMENTAL
Intervention: Call group (nurses called out to the operator before approaching the patient)
Number of subjects: 93
Study 24813167 — intervention group
Group type: COMPARATOR
Intervention: No-call group (nurses did not call out to the operator before approaching the patient)
Number of subjects: 93
Study 22090168 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise (SE)
Number of subjects: 111
Study 22090168 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent revascularization (ST)
Number of subjects: 111
Study 22090168 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical care (OMC)
Number of subjects: 111
Study 21034274 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic anti-reflux surgery (LARS) alone (group A)
Number of subjects: 1000
Study 21034274 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic anti-reflux surgery (LARS) with concomitant cholecystectomy (group B)
Number of subjects: 1000
Study 21034274 — intervention group
Group type: COMPARATOR
Intervention: Comparison of complications between group A and group B
Number of subjects: 1000
Study 18336399 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 cycles of single-agent paclitaxel (175 mg/m(2) over 3 h every 28 days)
Number of subjects: 0
Study 18336399 — intervention group
Group type: COMPARATOR
Intervention: Three cycles of the same treatment regimen (paclitaxel)
Number of subjects: 0
Study 18336399 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-cycle maintenance program with baseline CA-125 level <or=10 units/mL
Number of subjects: 0
Study 16181163 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 1.5 mg/d
Number of subjects: 430
Study 16181163 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 430
Study 12749512 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine (combined groups: 150, 300, 600, and 750 mg)
Number of subjects: 257
Study 12749512 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (12 mg)
Number of subjects: 257
Study 12749512 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 257
Study 12749512 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 257
Study 10556610 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurological patients
Number of subjects: 4
Study 10556610 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 4
Study 8712391 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol 1 mg/kg
Number of subjects: 13
Study 8712391 — intervention group
Group type: COMPARATOR
Intervention: Control (standard succinylcholine/methohexital anesthetic)
Number of subjects: 13
Study 1984710 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam 0.25 mg t.i.d. for 14 days
Number of subjects: 60
Study 1984710 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone 5 mg t.i.d. for 14 days
Number of subjects: 60
Study 1984710 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 29953951 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance before aerobic training (RA)
Number of subjects: 45
Study 29953951 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic before resistance training (AR)
Number of subjects: 45
Study 29953951 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 45
Study 27977699 — intervention group
Group type: EXPERIMENTAL
Intervention: Moral emotions elicited in everyday social interactions
Number of subjects: 312
Study 27977699 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative and quantitative methods
Number of subjects: 312
Study 27977699 — intervention group
Group type: EXPERIMENTAL
Intervention: Categorical systems based on participants' descriptions
Number of subjects: 312
Study 25450242 — intervention group
Group type: EXPERIMENTAL
Intervention: Lensx femtosecond laser‐assisted cataract surgery capsulotomy
Number of subjects: 90
Study 25450242 — intervention group
Group type: EXPERIMENTAL
Intervention: Lensar femtosecond laser‐assisted cataract surgery capsulotomy
Number of subjects: 90
Study 25450242 — intervention group
Group type: COMPARATOR
Intervention: Manual continuous curvilinear capsulorhexis
Number of subjects: 90
Study 22984102 — intervention group
Group type: EXPERIMENTAL
Intervention: Early class III protraction facemask treatment (PFG)
Number of subjects: 73
Study 22984102 — intervention group
Group type: COMPARATOR
Intervention: Control/no treatment group (CG)
Number of subjects: 73
Study 20636227 — intervention group
Group type: EXPERIMENTAL
Intervention: Red Yeast Rice (RYR) - HypoCol, 4 capsules/day
Number of subjects: 42
Study 20636227 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 18414905 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based physical activity program (12-week telephone counseling)
Number of subjects: 86
Study 18414905 — intervention group
Group type: COMPARATOR
Intervention: Contact control group
Number of subjects: 86